Evidence map›Paper›PMID 34834206›Full record

ReviewPharmaceutics2021

Glycyrrhizic Acid and Its Hydrolyzed Metabolite 18β-Glycyrrhetinic Acid as Specific Ligands for Targeting Nanosystems in the Treatment of Liver Cancer.

Luciano A Stecanella, Antonio P R Bitencourt, Gustavo Richter Vaz, Eride Quarta, José O C Silva Júnior, Alessandra Rossi

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Luciano A StecanellaLaboratory R&D Pharmaceutical and Cosmetic, Federal University of Pará, Street Augusto Correa 01, Belém 66075-110, Brazil.ORCID 0000-0002-2800-9002
Antonio P R BitencourtLaboratory R&D Pharmaceutical and Cosmetic, Federal University of Pará, Street Augusto Correa 01, Belém 66075-110, Brazil.
Gustavo Richter VazDepartment of Food and Drug, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.ORCID 0000-0003-0951-801X
Eride QuartaDepartment of Food and Drug, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.ORCID 0000-0003-0215-2350
José O C Silva JúniorLaboratory R&D Pharmaceutical and Cosmetic, Federal University of Pará, Street Augusto Correa 01, Belém 66075-110, Brazil.
Alessandra RossiDepartment of Food and Drug, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.ORCID 0000-0002-1480-753X
University of Parma · ITUniversidade Federal do Pará · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycyrrhizic acid and its hydrolyzed metabolite 18β-glycyrrhetinic acid, obtained from the plant

Indexed as

drug targetingglycyrrhetinic acidglycyrrhizic acidliver cancernanosystems

Identifiers

PMID34834206
PMCPMC8621092
OpenAlexW3210942072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.